World's Best Scientists 2026 revealed!
Gerd Fätkenheuer

Gerd Fätkenheuer

D-Index & Metrics

Microbiology

D-Index
86
Citations
44499
World Ranking
815
National Ranking
49

Medicine

D-Index
88
Citations
46093
World Ranking
12914
National Ranking
693

Gerd Fätkenheuer publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Gerd Fätkenheuer sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 407 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Gerd Fätkenheuer D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Gerd Fätkenheuer sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 86 D-Index — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Gerd Fätkenheuer is affiliated with the University of Cologne in Germany and has conducted extensive research primarily within the field of Medicine. Their work includes significant contributions to Infectious Diseases, Epidemiology, Virology, Surgery, and Emergency Medicine.

The scientist's research topics prominently cover areas related to SARS-CoV-2 and COVID-19 as well as HIV/AIDS, focusing on drug development, treatment, detection, testing, clinical research studies, and interventions. Specific topics include:

  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS drug development and treatment
  • SARS-CoV-2 detection and testing
  • COVID-19 Clinical Research Studies
  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • HIV-related health complications and treatments

Frequent coauthors collaborating with Gerd Fätkenheuer include Clara Lehmann, Florian Klein, Isabelle Suárez, Norma Jung, and Jan Rybniker.

Their scholarly articles have appeared in journals such as Infection, bioRxiv (Cold Spring Harbor Laboratory), HIV Medicine, BMC Public Health, and Open Forum Infectious Diseases.

Notable recent publications authored or coauthored by the scientist include:

  • Remdesivir for the Treatment of Covid-19 - Final Report (2020), New England Journal of Medicine
  • Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study (2021), The Lancet Regional Health - Europe
  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults (2020), JAMA
  • Remdesivir against COVID-19 and Other Viral Diseases (2020), Clinical Microbiology Reviews
  • Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans (2021), Cell Host & Microbe

The main fields of their publications emphasize infectious diseases and related subfields. The volume and scope suggest an active engagement in clinical and epidemiological aspects of infectious conditions, especially viral infections such as HIV and SARS-CoV-2.

Best Publications

  • Remdesivir for the Treatment of Covid-19 - Final Report.

    John H. Beigel;Kay M. Tomashek;Lori E. Dodd;Aneesh K. Mehta

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • CD4+ count-guided interruption of antiretroviral treatment.

    Wafaa El-Sadr;Wafaa El-Sadr;Jens D Lundgren;James Neaton;Fred Gordin

  • Initiation of antiretroviral therapy in early asymptomatic HIV infection

    Sean Emery;Shweta Sharma;Gerd Fätkenheuer;Josep M. Llibre

  • Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus

    Vance G. Fowler;Helen W. Boucher;G. Ralph Corey;Elias Abrutyn

  • Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

    Jonathan A C Sterne;Margaret May;Dominique Costagliola;Frank de Wolf

  • Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

    Marina Caskey;Florian Klein;Julio C. C. Lorenzi;Michael S. Seaman

  • Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study.

    Max Augustin;Philipp Schommers;Melanie Stecher;Felix Dewald

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

    Michael S. Saag;Constance A. Benson;Rajesh T. Gandhi;Jennifer F. Hoy

  • Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

    Gerd Fätkenheuer;Anton L Pozniak;Margaret A Johnson;Andreas Plettenberg

  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression

    Pilar Mendoza;Henning Gruell;Lilian Nogueira;Joy A. Pai

  • Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

    Marina Caskey;Till Schoofs;Henning Gruell;Allison Settler

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

    Michael S. Saag;Rajesh T. Gandhi;Jennifer F. Hoy;Raphael J. Landovitz

  • Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

    Gerd Fätkenheuer;Mark Nelson;Adriano Lazzarin;Irina Konourina

  • Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).

    Amanda Mocroft;Jens D Lundgren;Jens D Lundgren;Miriam Lewis Sabin;Antonella d'Arminio Monforte

  • Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

    Joseph J Eron;Benjamin Young;David A Cooper;Michael Youle

  • Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.

    G Chêne;J A C Sterne;M May;D Costagliola

  • Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

    Amanda Mocroft;Andrew N. Phillips;Jose Gatell;Bruno Ledergerber

  • Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.

    Gerd Fätkenheuer;Albert Theisen;Jürgen Rockstroh;Tanja Grabow

  • HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

    May Mt;Sterne Ja;Costagliola D;Sabin Ca

Frequent Co-Authors

Oliver A. Cornely
Oliver A. Cornely University of Cologne
Volker Diehl
Volker Diehl University of Cologne
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Jürgen K. Rockstroh
Jürgen K. Rockstroh University Hospital Bonn
Rolf Kaiser
Rolf Kaiser University of Cologne
Amanda Mocroft
Amanda Mocroft University College London
Harald Seifert
Harald Seifert University of Cologne
François Dabis
François Dabis University of Bordeaux
Margaret T May
Margaret T May University of Bristol

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to a variety of related online degrees and career pathways. For those interested in healthcare and patient support roles, becoming a child life specialist can be a rewarding option. This career focuses on improving the emotional well-being of children in clinical settings, blending knowledge of biology with patient care skills.

Additionally, students seeking flexible and accessible programs may explore degrees suited for diverse backgrounds. For example, the best degree for felons resource offers guidance for individuals with records to find reputable online degrees that can restart or redirect their careers.

Healthcare professionals looking to expand their expertise might consider becoming a functional nurse practitioner. This specialized role integrates holistic health approaches with clinical knowledge, which can complement a strong foundation in microbiology.

For those inclined toward administrative and coding roles within healthcare systems, obtaining the cpc certification can lead to careers in medical billing and coding, vital areas that support healthcare delivery and data management.

Best Scientists Citing Gerd Fätkenheuer

Trending Scientists

Recently Published Articles